Malondialdehyde formation pathway (MDA formation pathway)

The Malondialdehyde (MDA) formation pathway is a biochemical process involving the degradation of polyunsaturated fatty acids (PUFAs) through lipid peroxidation (Marnett, 1999, PMID: 10232638). This process can occur non-enzymatically via reactive oxygen species (ROS) or enzymatically as a byproduct of thromboxane A2 synthesis (Hecker et al., 1987, PMID: 3110431). MDA is a highly reactive dialdehyde that serves as a primary biomarker for oxidative stress and is capable of forming DNA and protein adducts, which are mutagenic and cytotoxic (Gaweł et al., 2004, PMID: 15510115). Elevated levels of MDA are associated with various pathological conditions, including atherosclerosis, diabetes, and neurodegenerative diseases like Alzheimer's (Zarkovic, 2003, PMID: 12893418). Therapeutic interventions targeting this pathway generally focus on antioxidant supplementation or the use of radical scavengers to mitigate oxidative damage and prevent the accumulation of toxic lipid-derived aldehydes (Ayala et al., 2014, PMID: 24999379).

Other names

Lipid peroxidation pathwayMDA productionPolyunsaturated fatty acid degradation

Therapeutic agents typically act by scavenging reactive oxygen species (ROS) to prevent the initiation of lipid peroxidation or by directly neutralizing reactive aldehydes like MDA to prevent adduct formation (Ayala et al., 2014, PMID: 24999379).